-
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
•
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO) of 45,398,800 shares on the Hong Kong Stock Exchange (HKEX) on November 26, following the receipt of approval from the exchange earlier this week. The company has priced each share at 12.56, aiming to raise…
-
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
•
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing hearing by The Stock Exchange of Hong Kong Limited for its initial public offering (IPO). While the price and other key details have not been disclosed at this stage, the company’s listing marks a significant…
-
PegBio Files for IPO on Hong Kong Stock Exchange
•
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant step towards going public with an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). While the price and other specific details of the offering are yet to be disclosed, the move…
-
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin off its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm), for an initial public offering (IPO) on the Hong Kong Stock Exchange. This follows an earlier aborted effort to list on Shanghai’s Sci-Tech Innovation Board (STAR)…
-
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
•
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering (IPO) application of 4,705,150 shares accepted for review by the Beijing Stock Exchange. This marks the first such move by a pre-revenue biotech company following the China Securities Regulatory Commission’s (CSRC) tightening of IPO rules…
-
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
•
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit products, has submitted an updated initial public offering (IPO) prospectus to the Hong Kong Stock Exchange. The document reveals the company’s financial performance as of June 2024. During the first half of the year, Mirxes…
-
Hengrui Medicine Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning a secondary listing on the Hong Kong Stock Exchange, according to multiple media sources. The move is anticipated to raise approximately USD 2 billion (RMB 14 billion) and comes amidst concerns regarding “difficulty in financing…
-
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
•
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in China, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 14,588,000 shares at a price of HKD 22 each, raising a total of HKD 320 million (USD…
-
Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation
•
On October 18, 2024, the Hong Kong Stock Exchange announced that Beijing Biostar Pharmaceuticals Co., Ltd. is set to go public following a successful hearing. CCB International and CITIC Securities International will serve as joint sponsors for the listing. According to the prospectus, Biostar is a biotechnology company driven by…
-
Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange
•
China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem cell (PSC) derived cell therapies, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Details of the offering have not been disclosed at this stage. Established in 2017, Zephyrm Bio…
-
Zephyrm Biotechnologies Aims for HKEX Main Board with Innovative Cell Therapy Products
•
Zephyrm Biotechnologies Co., Ltd. (hereinafter referred to as “Zephyrm Bio”) officially submitted its prospectus to the Hong Kong Stock Exchange (HKEX) on September 30, 2024, with the intention to list on the Main Board, with CICC acting as the sole sponsor. Established in 2017, Zephyrm Bio, a clinical-stage biopharmaceutical company,…
-
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
•
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry Co., Ltd, has made a notable debut by initiating an initial public offering (IPO) on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This marks the first pharmaceutical company to go public on this platform…
-
Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials
•
HONG KONG—Duality Biotherapeutics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is planning an initial public offering (IPO) on the Hong Kong Stock Exchange. While the unit price and further details remain under wraps, the company’s ambitions are clear, with a robust pipeline of 12 innovative ADCs…
-
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
•
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD per share for a total of 2,000,000 ordinary shares. The shares have received approval for listing on the Nasdaq Capital Market and are set to begin trading on August 23, 2024, under the ticker symbol…
-
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
•
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total…
-
Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) since October 2022, is reportedly planning a secondary listing on the Hong Kong Stock Exchange (HKEX). The firm’s IPO is being co-sponsored by prominent investment banks Goldman Sachs, J.P. Morgan, and…
-
Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum
•
A number of healthcare companies are seeking to capitalize on the recovering market conditions by filing for initial public offerings (IPOs) on the Hong Kong Stock Exchange (HKEX), a venue that has been gaining traction among life sciences companies for their public listings. According to the HKEX website, recent IPO…
-
Jianke.com, China’s Leading Chronic Disease Management Platform, Files for Hong Kong IPO
•
Jianke.com, a China-based smart healthcare service platform, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, with shares priced between HKD 7.6 and 8.36 per share. The company aims to raise HKD 63.07 million (USD 8.01 million) through the IPO of 23.8 million shares. Established…
-
Jiangxi Fushine’s Subsidiary LinkChem Eyes Hong Kong IPO Amid Strong Revenue Growth
•
Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its subsidiary, LinkChem, intends to conduct an initial public offering (IPO) on the Hong Kong Stock Exchange. At this stage, no further details regarding the IPO have been disclosed. Established in 2011 and headquartered in Shanghai,…
-
Cloudbreak Pharma Files for Hong Kong IPO with Focus on Ophthalmic Innovations
•
Cloudbreak Pharma Inc., a Cayman Islands-registered pharmaceutical company, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange, with key details still under wraps. In 2023, the company reported revenues of USD 880,000 and a net loss of USD 129 million, with research and development (R&D)…
-
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
•
QuantumPharm Inc., operating under the name Xtalpi Inc., has successfully conducted an initial public offering (IPO) on the Hong Kong Stock Exchange, raising HKD 1.13 billion (USD 144.5 million). The shares of Xtalpi, listed under the ticker symbol 02228, were priced at HKD 6.03 per share. Xtalpi is a pioneer…
-
Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share
•
Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has set the pricing range for its initial public offering (IPO) on the Hong Kong Stock Exchange. The price band is set between HKD 14.6 and 16.8 per share, which equates to approximately USD 1.87 to…
-
Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation of an initial public offering (IPO) on Shanghai’s Sci-Tech Innovation Board (STAR) for its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd (Xuanzhu Biopharm). Xuanzhu Biopharm, which concentrates on therapeutic areas such as oncology, metabolism, anti-infection, and digestion,…
-
Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in China, has announced that its board of directors has given the green light to pre-planning activities for the spin-off of its subsidiary, Fosun Health. The company is currently in discussions regarding the potential initial public…
-
Sunho Biologics Lists on HKEX with HKD 461 Million Biotech IPO
•
Sunho Biologics, Inc., (HKG: 2898) a clinical-stage biopharmaceutical company based in China specializing in biologic preparations for the treatment of cancer and autoimmune diseases, has successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 34,151,800 shares priced at HKD 13.5 per share, resulting…
-
Protein Drug Developer B&K Co., Ltd from Qingdao Eyes Hong Kong IPO
•
B&K Co., Ltd, a biopharmaceutical company specializing in protein drug development and headquartered in Qingdao, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company’s IPO details, including pricing, have not yet been disclosed. Since its establishment in 2012, B&K has focused on research…
-
Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO
•
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the Hong Kong Stock Exchange (HKEX) in anticipation of a public listing. The firm is targeting a minimum capital raise of USD 100 million, aiming for a valuation of at least USD 600 million. This follows…
-
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
•
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed at enhancing the capital market’s functionality, optimizing resource allocation, and bolstering the high-level development of technology enterprises.
-
LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal
•
The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) has been suspended for review, following the withdrawal of the filing and sponsorship. The Beijing-based company, which specializes in the research and development (R&D), manufacturing, and marketing of medical cone-shaped beam…
-
Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline
•
Jiangsu QYuns Therapeutics Co., Ltd. (HKG: 2509), based in China, is poised to launch an initial public offering (IPO) of 12,046,400 shares on the Hong Kong Stock Exchange, with a pricing range set between HKD 19.8 and HKD 20.2 per share. The company anticipates raising between HKD 239 million and…
-
TYK Medicines Files for IPO on HKSE Amid Rising Losses and Expanding Drug Pipeline
•
Zhejiang-based TYK Medicines Inc. (HKG: 2410) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company reported revenues of RMB 44 million and a loss of RMB 312 million in 2022, primarily generated through a licensing agreement with Livzon Pharma. In the first…
-
Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price
•
China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public offering (IPO) on the Hong Kong Stock Exchange, with shares priced at HKD 14.28 per share. The stock opened trading at HKD 9.8 per share and, as of the noon close, had risen to HKD…
-
Weigao Blood Purification Aims for USD 190 Million in Shanghai Stock Exchange IPO
•
Shandong Weigao Blood Purification Products Co., Ltd, a dominant player in China’s blood purification sector, has submitted an initial public offering (IPO) application to the Shanghai Stock Exchange (SSE). The exchange has accepted the filing for review, with the company eyeing a substantial capital injection of RMB 1.351 billion (USD…
-
HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO
•
HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange this week. The company issued 24 million shares, each priced at HKD 11.5, resulting in a net proceeds amount of HKD 194.1 million (USD 25 million). Founded…
-
WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange
•
WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman Inc., (HKG: 2268) to the Hong Kong Stock Exchange on Friday, November 17, 2023. Through the global offer, WuXi XDC issued 178.44 million shares at a price of HK 20.60 per share. The gross proceeds…
-
Jiangxi Rimag Group Eyes Hong Kong IPO to Expand Medical Imaging Services
•
Jiangxi Rimag Group Co., Ltd (HKG: 2522), a China-based medical imaging specialist, is planning an initial public offering (IPO) on the Hong Kong Stock Exchange, with details currently being compiled. The company has previously raised a war chest of RMB 900 million through several financing rounds. Founded in 2014, Rimag…
-
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
•
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans for its subsidiary, Lizhu Reagent. The company has decided to terminate its initial plan to spin off Lizhu Reagent for a listing on the Shenzhen Stock Exchange’s ChiNext board. Instead, it will file for a…
-
WuXi XDC Aims for HKEX Listing with IPO of 178.4 Million Shares
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), is preparing for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 178.4 million shares, priced between HKD 19.9…
-
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
•
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange, although specific pricing and additional details remain undisclosed at this time. This strategic move aims to enhance the company’s visibility and funding capabilities in the…
-
Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million
•
Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on the Nasdaq exchange last week. The company issued 2.5 million American depositary shares at a price of USD 23 each, resulting in a gross proceeds of USD 57.5 million. In addition, Adlai Nortye secured USD…
-
Sandoz Becomes Independent After Spin-Off from Novartis
•
Switzerland-based generic and biosimilar drug maker Sandoz (SWX: SDZ) officially became a fully independent company last week, completing its separation from Novartis (NYSE: NVS) as previously announced. The decision to spin off Sandoz was first presented in 2022, aimed at establishing a global leader in generics and biosimilars while allowing…
-
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
•
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs and drug immunotherapies, is poised to raise HKD 220 million (USD 28.4 million) through an initial public offering (IPO) on the Hong Kong Stock Exchange. The company plans to issue 11,001,200 shares at a price…
